Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

18F-fluciclovine PET or PSMA PET for prostate cancer imaging?

Turkbey B, Choyke PL.

Nat Rev Urol. 2020 Jan;17(1):9-10. doi: 10.1038/s41585-019-0255-6. No abstract available.

PMID:
31676885
2.

Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.

Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F.

J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14.

3.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
4.

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.

Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613.

PMID:
31375469
5.

A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.

Pernthaler B, Kulnik R, Gstettner C, Salamon S, Aigner RM, Kvaternik H.

Clin Nucl Med. 2019 Oct;44(10):e566-e573. doi: 10.1097/RLU.0000000000002703.

PMID:
31283605
6.

Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.

Song H, Harrison C, Duan H, Guja K, Hatami N, Franc B, Moradi F, Mari Aparici C, Davidzon G, Iagaru A.

J Nucl Med. 2019 Oct 18. pii: jnumed.119.231654. doi: 10.2967/jnumed.119.231654. [Epub ahead of print]

PMID:
31628216
7.

18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.

Selnæs KM, Krüger-Stokke B, Elschot M, Willoch F, Størkersen Ø, Sandsmark E, Moestue SA, Tessem MB, Halvorsen D, Kjøbli E, Angelsen A, Langørgen S, Bertilsson H, Bathen TF.

Eur Radiol. 2018 Aug;28(8):3151-3159. doi: 10.1007/s00330-017-5213-1. Epub 2018 Jan 2.

PMID:
29294158
8.

A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer.

Elschot M, Selnæs KM, Sandsmark E, Krüger-Stokke B, Størkersen Ø, Tessem MB, Moestue SA, Bertilsson H, Bathen TF.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):695-703. doi: 10.1007/s00259-016-3562-7. Epub 2016 Nov 5.

PMID:
27817158
9.

Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using 18F-Fluciclovine PET/CT.

Miller MP, Kostakoglu L, Pryma D, Yu JQ, Chau A, Perlman E, Clarke B, Rosen D, Ward P.

J Nucl Med. 2017 Oct;58(10):1596-1602. doi: 10.2967/jnumed.116.188375. Epub 2017 Apr 6.

10.

Prospective evaluation of fluciclovine (18F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients.

Akin-Akintayo O, Tade F, Mittal P, Moreno C, Nieh PT, Rossi P, Patil D, Halkar R, Fei B, Master V, Jani AB, Kitajima H, Osunkoya AO, Ormenisan-Gherasim C, Goodman MM, Schuster DM.

Eur J Radiol. 2018 May;102:1-8. doi: 10.1016/j.ejrad.2018.02.006. Epub 2018 Feb 24.

11.

Best Practices for 18F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists.

Tade FI, Sajdak RA, Gabriel M, Wagner RH, Savir-Baruch B.

J Nucl Med Technol. 2019 Dec;47(4):282-287. doi: 10.2967/jnmt.119.227116. Epub 2019 Jun 10. Review.

PMID:
31182661
12.

Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18.

13.

The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer.

Calais J, Cao M, Nickols NG.

J Nucl Med. 2018 Apr;59(4):557-567. doi: 10.2967/jnumed.117.196444. Epub 2018 Jan 4.

14.

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Amorim BJ, Prabhu V, Marco SS, Gervais D, Palmer WE, Heidari P, Vangel M, Saylor PJ, Catalano OA.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):105-114. doi: 10.1007/s00259-019-04506-1. Epub 2019 Sep 6.

PMID:
31492992
15.

Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.

Chau A, Gardiner P, Colletti PM, Jadvar H.

Clin Nucl Med. 2018 Jul;43(7):e226-e231. doi: 10.1097/RLU.0000000000002130.

16.

18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.

Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, Pettinato C, Martorana G, Fanti S.

Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849.

PMID:
26053708
17.

Impact of 18F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.

Jani AB, Schreibmann E, Rossi PJ, Shelton J, Godette K, Nieh P, Master VA, Kucuk O, Goodman M, Halkar R, Cooper S, Chen Z, Schuster DM.

J Nucl Med. 2017 Mar;58(3):412-418. doi: 10.2967/jnumed.116.176057. Epub 2016 Sep 8.

18.

Combined 18F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer.

Elschot M, Selnæs KM, Sandsmark E, Krüger-Stokke B, Størkersen Ø, Giskeødegård GF, Tessem MB, Moestue SA, Bertilsson H, Bathen TF.

J Nucl Med. 2018 May;59(5):762-768. doi: 10.2967/jnumed.117.198598. Epub 2017 Oct 6.

19.

Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer.

McDonald AM, Galgano SJ, McConathy JE, Yang ES, Dobelbower MC, Jacob R, Rais-Bahrami S, Nix JW, Popple RA, Fiveash JB.

Adv Radiat Oncol. 2019 Jun 19;4(4):649-658. doi: 10.1016/j.adro.2019.05.008. eCollection 2019 Oct-Dec.

20.

[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.

Nanni C, Zanoni L, Bach-Gansmo T, Minn H, Willoch F, Bogsrud TV, Edward EP, Savir-Baruch B, Teoh E, Ingram F, Fanti S, Schuster DM.

Eur J Nucl Med Mol Imaging. 2019 Dec 11. doi: 10.1007/s00259-019-04614-y. [Epub ahead of print]

PMID:
31822959

Supplemental Content

Support Center